NASDAQ:VTGN

VistaGen Therapeutics - VTGN Stock Forecast, Price & News

$0.14

0.00 (-0.79%)

(As of 03/29/2023 03:52 PM ET)

Add

Compare

Today's Range: $0.14
▼
$0.15
50-Day Range: $0.13
▼
$0.30
52-Week Range: $0.08
▼
$1.79

Volume: 1.98 million shs
Average Volume: 6.34 million shs
Market Capitalization: $30.29 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Institutional Ownership

VistaGen Therapeutics MarketRank™ Forecast

Analyst Rating: N/A
Upside/Downside: N/A
Short Interest: Healthy
3.91% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: -0.15
Based on 6 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($0.26) to ($0.15) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.09 out of 5 stars

Medical Sector

983rd out of 999 stocks

Pharmaceutical Preparations Industry

482nd out of 489 stocks

N/A

Analyst's Opinion

Consensus Rating
There is not enough analysis data for VistaGen Therapeutics.

3.0

Short Interest

Percentage of Shares Shorted
3.91% of the outstanding shares of VistaGen Therapeutics have been sold short.
Short Interest Ratio / Days to Cover
VistaGen Therapeutics has a short interest ratio ("days to cover") of 1.2, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in VistaGen Therapeutics has recently increased by 17.40%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
VistaGen Therapeutics does not currently pay a dividend.
Dividend Growth
VistaGen Therapeutics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for VTGN.

1.0

News and Social Media Coverage

News Sentiment
VistaGen Therapeutics has a news sentiment score of -0.15. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.61 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 6 news articles for VistaGen Therapeutics this week, compared to 1 article on an average week.
Search Interest
Only 14 people have searched for VTGN on MarketBeat in the last 30 days. This is a decrease of -64% compared to the previous 30 days.
MarketBeat Follows
Only 3 people have added VistaGen Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -80% compared to the previous 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, VistaGen Therapeutics insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 4.01% of the stock of VistaGen Therapeutics is held by insiders.
Percentage Held by Institutions
Only 27.29% of the stock of VistaGen Therapeutics is held by institutions.

1.3

Earnings and Valuation

Earnings Growth
Earnings for VistaGen Therapeutics are expected to grow in the coming year, from ($0.26) to ($0.15) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of VistaGen Therapeutics is -0.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of VistaGen Therapeutics is -0.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
VistaGen Therapeutics has a P/B Ratio of 0.44. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About VistaGen Therapeutics (NASDAQ:VTGN) Stock

VistaGen Therapeutics, Inc. is a clinical-stage biopharmaceutical company committed to developing and commercializing new generation medications that go beyond the current standard of care for anxiety, depression, and other central nervous system disorders. Its portfolio includes PH94B, a neuroactive nasal spray with potential to treat multiple anxiety disorders that the company is currently preparing for phase III clinical trial for social anxiety disorder, PH10, a neuroactive nasal spray that the company is planning for phase 2b development as a stand-alone treatment for major depressive disorder (MDD), and AV-101, which the company is developing for the treatment of MDD, suicidal ideation, neuropathic pain, levodopa-induced dyskinesia, and epilepsy. The company was founded by H. Ralph Snodgrass and Gordon Keller on May 26, 1998 and is headquartered in South San Francisco, CA.

Receive VTGN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for VistaGen Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

VTGN Stock News Headlines

March 28, 2023 | americanbankingnews.com

VistaGen Therapeutics, Inc. to Post FY2023 Earnings of ($0.26) Per Share, William Blair Forecasts (NASDAQ:VTGN)

March 24, 2023 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: VistaGen Therapeutics (VTGN) and Humacyte (HUMA)

March 29, 2023 | Tradewins (Ad)

Modern Day Options Trading For Beginners!

These days it takes more than willpower to succeed on Wall Street and for new traders, even small mistakes can sink an account! With "Your Guide To Successful Options Trading" by expert Wendy Kirkland, you can avoid new trader pitfalls and learn to earn in this vicious market.

March 22, 2023 | seekingalpha.com

Vistagen up 17% after Phase 3 data for anxiety candidate

March 22, 2023 | finance.yahoo.com

Vistagen Announces Positive Data in Fasedienol (PH94B) Phase 3 Open-Label Study in Adults with Social Anxiety Disorder

March 9, 2023 | markets.businessinsider.com

Maxim Group Sticks to Its Hold Rating for VistaGen Therapeutics (VTGN)

March 8, 2023 | finance.yahoo.com

Vistagen Announces Completion of Last Patient, Last Visit in Phase 1 Clinical Trial of Itruvone (PH10), an Investigational Pherine Nasal Spray for Major Depressive Disorder

March 2, 2023 | finance.yahoo.com

Vistagen to Present at Cowen 43rd Annual Health Care Conference

March 29, 2023 | Investor Place Media (Ad)

The "King Of Quants" sees 10X potential...

Eric Fry believes he just discovered America's next "Wealth Supercluster" and it's forming in the place you'd least expect. Investors are already flocking there for a chance at 1,000%+ returns. Here's how you could join them before it's too late...

March 1, 2023 | finance.yahoo.com

Vistagen Announces Issuance of U.S. Patent for PH80 Nasal Spray for Treatment of Migraine

February 9, 2023 | msn.com

VistaGen Therapeutics's Return On Capital Employed Insights

February 8, 2023 | finance.yahoo.com

VistaGen Shares Plunge Amid Uncertainty Around Its Anxiety Trial

February 7, 2023 | markets.businessinsider.com

Here's what Wall Street expects from VistaGen Therapeutics's earnings

February 6, 2023 | msn.com

Preview: VistaGen Therapeutics's Earnings

February 6, 2023 | finance.yahoo.com

Vistagen to Report Fiscal Year 2023 Third Quarter Financial Results on February 7, 2023

February 2, 2023 | finance.yahoo.com

Vistagen Announces Closing of Pherin Pharmaceuticals Acquisition

January 26, 2023 | benzinga.com

InvestorNewsBreaks — VistaGen Therapeutics Inc. (NASDAQ: VTGN) Doses First Participants in PH10 Phase 1 Clinical Trial

January 25, 2023 | seekingalpha.com

VTGN VistaGen Therapeutics, Inc.

January 24, 2023 | finance.yahoo.com

Vistagen Announces First Participants Dosed in Phase 1 Clinical Trial of PH10, an Investigational Pherine Nasal Spray for Major Depressive Disorder

January 10, 2023 | finance.yahoo.com

Vistagen Announces Completion of Last Patient, Last Visit in Phase 2 Clinical Trial of PH94B for the Treatment of Adjustment Disorder with Anxiety

January 5, 2023 | benzinga.com

VistaGen Therapeutics Stock (NASDAQ:VTGN), Quotes and News Summary

December 22, 2022 | msn.com

VistaGen Therapeutics Earnings Perspective: Return On Capital Employed

December 21, 2022 | finance.yahoo.com

Vistagen to Acquire Pherin Pharmaceuticals

December 21, 2022 | finance.yahoo.com

Vistagen Strengthens Its Neurology Focused Pipeline With Pherin Pharma Acquisition

December 6, 2022 | marketwatch.com

Vistagen Therapeutics Shares Rise on FDA Fast-Track Designation >VTGN

December 6, 2022 | finance.yahoo.com

Vistagen Receives FDA Fast Track Designation for Development of PH10 to Treat Major Depressive Disorder

November 30, 2022 | finance.yahoo.com

Vistagen Receives FDA "Study May Proceed" Letter Under its Investigational New Drug Application for PH10 to Treat Major Depressive Disorder

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive VTGN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for VistaGen Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

VTGN Company Calendar

Last Earnings: 2/07/2023
Today: 3/29/2023
Fiscal Year End: 3/31/2023
Next Earnings (Estimated): 6/22/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:VTGN
CUSIP: N/A
CIK: 1411685
Web: www.vistagen.com
Phone: (650) 577-3600
Fax: 888-482-2602
Employees: 31
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): ($0.31)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-47,760,000.00
Net Margins: -5,614.37%
Pretax Margin: -5,613.99%
Return on Equity: -158.24%
Return on Assets: -125.05%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 6.08
Quick Ratio: 6.08

Sales & Book Value

Annual Sales: $1.11 million
Price / Sales: 27.51
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.31 per share
Price / Book: 0.45

Miscellaneous

Outstanding Shares: 219,330,000
Free Float: 210,531,000
Market Cap: $30.53 million
Optionable: Not Optionable
Beta: 1.09

Key Executives

Shawn K. Singh
Chief Executive Officer & Director

Jerrold D. Dotson
Chief Financial Officer, Secretary & VP

Ellis Wilson
Vice President-Global Clinical Operations

Jessica R. Haskell
Vice President & Associate General Counsel

Ann Cunningham
Director & Chief Commercial Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

VTGN Stock - Frequently Asked Questions

Should I buy or sell VistaGen Therapeutics stock right now?: 4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for VistaGen Therapeutics in the last year. There are currently 4 hold ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" VTGN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in VTGN, but not buy additional shares or sell existing shares.
View VTGN analyst ratings or view top-rated stocks.
How have VTGN shares performed in 2023?: VistaGen Therapeutics' stock was trading at $0.1030 at the beginning of 2023. Since then, VTGN shares have increased by 34.1% and is now trading at $0.1381.
View the best growth stocks for 2023 here.
When is VistaGen Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, June 22nd 2023.
View our VTGN earnings forecast.
How were VistaGen Therapeutics' earnings last quarter?: VistaGen Therapeutics, Inc. (NASDAQ:VTGN) posted its quarterly earnings results on Tuesday, February, 7th. The company reported ($0.05) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.06) by $0.01. The firm earned $0.18 million during the quarter, compared to analysts' expectations of $0.31 million. VistaGen Therapeutics had a negative trailing twelve-month return on equity of 158.24% and a negative net margin of 5,614.37%.
What ETF holds VistaGen Therapeutics' stock ?: Psyk Etf holds 77,466 shares of VTGN stock, representing 0.60% of its portfolio.
What other stocks do shareholders of VistaGen Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other VistaGen Therapeutics investors own include Highpower International (HPJ), AK Steel (AKS), Ayala Pharmaceuticals (ADXS), Matinas BioPharma (MTNB), Rite Aid (RAD), Sorrento Therapeutics (SRNE), Lithium Americas (LAC), ImmunoGen (IMGN), Yamana Gold (AUY) and CRISPR Therapeutics (CRSP).

What is VistaGen Therapeutics' stock symbol?: VistaGen Therapeutics trades on the NASDAQ under the ticker symbol "VTGN."
Who are VistaGen Therapeutics' major shareholders?: VistaGen Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include GSA Capital Partners LLP (2.32%), Geode Capital Management LLC (1.49%), Two Sigma Investments LP (0.30%), MAI Capital Management (0.30%), Alliancebernstein L.P. (0.14%) and GPS Wealth Strategies Group LLC (0.12%). Insiders that own company stock include H Ralph Snodgrass, Jerrold Duane Dotson, Jerry B Gin, Reid G Adler, Shawn Singh and Venrock Healthcare Capital Par.
View institutional ownership trends.
How do I buy shares of VistaGen Therapeutics?: Shares of VTGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is VistaGen Therapeutics' stock price today?: One share of VTGN stock can currently be purchased for approximately $0.14.
How much money does VistaGen Therapeutics make?: VistaGen Therapeutics (NASDAQ:VTGN) has a market capitalization of $30.29 million and generates $1.11 million in revenue each year. The company earns $-47,760,000.00 in net income (profit) each year or ($0.31) on an earnings per share basis.
How can I contact VistaGen Therapeutics?: VistaGen Therapeutics' mailing address is 343 ALLERTON AVENUE, SOUTH SAN FRANCISCO CA, 94080. The official website for the company is www.vistagen.com. The company can be reached via phone at (650) 577-3600, via email at ir@vistagen.com, or via fax at 888-482-2602.

This page (NASDAQ:VTGN) was last updated on 3/29/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

VistaGen Therapeutics - VTGN Stock Forecast, Price & News

VistaGen Therapeutics MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About VistaGen Therapeutics (NASDAQ:VTGN) Stock

VTGN Stock News Headlines

VTGN Company Calendar

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

VTGN Stock - Frequently Asked Questions

Overall MarketRank^™